CRISPR
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
CRISPR Therapeutics AG (CRSP): The Biotech Stock with Biggest Upside Potential
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
Correcting Genetic Spelling Errors With Next-Generation Crispr
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Editas, after slow start, outlines plan to catch other CRISPR companies
Promising Developments and Strategic Partnerships Drive Crispr Therapeutics’ Growth Potential
Genetic Engineering
Scientists say they are close to resurrecting a lost species. Is the age of de-extinction upon us?
Dallas-based tech company secures $200M to support de-extinction efforts
Dallas company raises $200M for 'Jurassic Park-style' effort to bring back woolly mammoths
A new era in genetic engineering: Researchers present single tool with multiple gene editing functions
De-extinction: Scientists are 'close' to bringing back extinct species in major breakthrough
Unlocking tomato regeneration: microRNA396's surprising role
Colossal Raises $200 Million From Dodger Co-Owner, Hollywood Mega Producer
Colossal Biosciences valued at more than $10B after latest funding round
Texas Business Valued at more than $10 Billion
Gene Editing
Rice breeders explore gene editing to enhance nighttime heat tolerance
Gene-edited soil bacteria could provide third source of nitrogen for corn production
This $10B Texas Startup Wants to Bring Back Extinct Animals Through Gene-Editing
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year
New gene-editing treatment extends lifespan in mice with prion disease
Luke O'Neill: The Science behind gene editing
The scientists trying to bring the woolly mammoth back to life
Colossal Biosciences raises $200M at $10.2B valuation to bring back woolly mammoths
UK presses ahead with gene editing plans despite EU warnings
CRISPR Therapy
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
New Approach Aims to Make CRISPR Therapy Safer and More Effective
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
Developing a CRISPR therapy for muscular dystrophy
CRISPR therapy corrects muscular dystrophy mutations and regrows muscles in mice
Bay Area scientists awarded White House medals for science and technology
Vertex, startup Orna to partner on gene editing research
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
In biopharma, mega-deals surged as VCs were more selective
Correcting Genetic Spelling Errors With Next-Generation Crispr
DNA
An Entire Book Was Written in DNA—and You Can Buy It for $60
Lone Tree murder cold case tainted by state DNA scientist, DA says
How Genomics Uses DNA And Tech To Make Healthcare Accessible To All
Man DNA tests Rescue Dog To Find Out What Breed He Is, Shocked by Results
Sentence issued in 1999 Michigan sexual assault case solved with DNA research
Who run the world? Celtic girls! New DNA study reveals overlooked power of women in British iron age
Hive Mentality: Is Behavior Programmed Into DNA?
Ancient DNA from graves reveals "jaw-dropping" discovery about Iron Age women in U.K., scientists say
DNA of teens does not match DNA from scene of killing of Chris Paul's grandfather, expert says
DNA Sequencing
The bacterium that transformed DNA sequencing
Global DNA sequencing market to witness 18.6% CAGR growth through 2029
Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers
JPM25: Regeneron, Illumina and more back Truveta for 10M genome sequencing project
Bloomberg Businessweek: DNA/RNA Sequencing
DNA sequencing could help conserve rare carp species
Cold Cases: Genetic Genealogy making breakthroughs with decades old DNA samples